These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29529307)

  • 21. Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting.
    Lau AN; Wong-Pack M; Rodjanapiches R; Ioannidis G; Wade S; Spangler L; Balasubramanian A; Pannacciulli N; Lin CJF; Roy-Gayos P; Bensen WG; Bensen R; Adachi JD
    J Rheumatol; 2018 Feb; 45(2):170-176. PubMed ID: 29142041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.
    Park DJ; Choi SJ; Shin K; Kim HA; Park YB; Kang SW; Kwok SK; Kim SK; Nam EJ; Sung YK; Lee J; Lee CH; Jeon CH; Lee SS
    Clin Rheumatol; 2017 May; 36(5):1013-1022. PubMed ID: 28243760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
    Arkema EV; Jonsson J; Baecklund E; Bruchfeld J; Feltelius N; Askling J;
    Ann Rheum Dis; 2015 Jun; 74(6):1212-7. PubMed ID: 24608401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.
    Galloway JB; Hyrich KL; Mercer LK; Dixon WG; Fu B; Ustianowski AP; Watson KD; Lunt M; Symmons DP; ;
    Rheumatology (Oxford); 2011 Jan; 50(1):124-31. PubMed ID: 20675706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients.
    Pamuk ÖN; Kalyoncu U; Aksu K; Omma A; Pehlivan Y; Çağatay Y; Küçükşahin O; Dönmez S; Çetin GY; Mercan R; Bayındır Ö; Çefle A; Yıldız F; Balkarlı A; Kılıç L; Çakır N; Kısacık B; Öksüz MF; Çobankara V; Onat AM; Sayarlıoğlu M; Öztürk MA; Pamuk GE; Akkoç N
    Rheumatol Int; 2016 Jul; 36(7):945-53. PubMed ID: 27221456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
    Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
    Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.
    Mercer LK; Green AC; Galloway JB; Davies R; Lunt M; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2012 Jun; 71(6):869-74. PubMed ID: 22241900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.
    Salmon JH; Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Meyer O; Solau-Gervais E; Marcelli C; Bardin T; Pane I; Baron G; Perrodeau E; Mariette X;
    Ann Rheum Dis; 2016 Jun; 75(6):1108-13. PubMed ID: 26048170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study.
    Aaltonen KJ; Virkki LM; Jämsen E; Sokka T; Konttinen YT; Peltomaa R; Tuompo R; Yli-Kerttula T; Kortelainen S; Ahokas-Tuohinto P; Blom M; Nordström DC
    Semin Arthritis Rheum; 2013 Aug; 43(1):55-62. PubMed ID: 23481417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment.
    Cho SK; Kim D; Won S; Han M; Lee J; Jang EJ; Kim TH; Bae SC; Sung YK
    Semin Arthritis Rheum; 2017 Aug; 47(1):102-107. PubMed ID: 28216194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry.
    Harrold LR; Reed GW; Karki C; Magner R; Shewade A; John A; Kremer JM; Greenberg JD
    Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1888-1893. PubMed ID: 27111064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. British Society for Rheumatology Biologics Register.
    Silman A; Symmons D; Scott DG; Griffiths I
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii28-9. PubMed ID: 14532144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study.
    Cipriani P; Berardicurti O; Masedu F; D'Onofrio F; Navarini L; Ruscitti P; Maruotti N; Margiotta DP; Liakouli V; Di Benedetto P; Carubbi F; Valenti M; Cantatore FP; Afeltra A; Giacomelli R
    Clin Rheumatol; 2017 Feb; 36(2):251-260. PubMed ID: 27783237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
    Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
    Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.
    Holroyd CR; Seth R; Bukhari M; Malaviya A; Holmes C; Curtis E; Chan C; Yusuf MA; Litwic A; Smolen S; Topliffe J; Bennett S; Humphreys J; Green M; Ledingham J
    Rheumatology (Oxford); 2019 Feb; 58(2):e3-e42. PubMed ID: 30137552
    [No Abstract]   [Full Text] [Related]  

  • 39. Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Chadwick L; Kearsley-Fleet L; Brown N; ; ; Watson KD; Lunt M; Symmons DPM; Hyrich KL
    Rheumatology (Oxford); 2020 Mar; 59(3):559-567. PubMed ID: 31722431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.
    Strangfeld A; Hierse F; Rau R; Burmester GR; Krummel-Lorenz B; Demary W; Listing J; Zink A
    Arthritis Res Ther; 2010; 12(1):R5. PubMed ID: 20064207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.